Archive


Category: abrocitinib

  • Pfizer gets first approval, in UK, for Xeljanz follow-up Cibinqo

    Pfizer has claimed its first regulatory approval worldwide for Cibinqo, its JAK inhibitor for atopic dermatitis, from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). The green light covers England, Scotland Wales, as Northern Ireland remains under the EU regulatory framework, and covers once-daily use of the orally-active drug in adolescents aged over 12 […]

  • FDA sets April verdict for Pfizer’s “underestimated” atopic dermatitis drug

    Pfizer could be just a few months away from getting FDA approval for its JAK1 inhibitor abrocitinib in atopic dermatitis, a drug that CEO Albert Bourla believes hasn’t been given the credit it is due by Wall Street analysts. The US regulator has started a priority review of abrocitinib for mediate to severe atopic dermatitis […]